Diagnostik und Therapie der Plattenepithel- und Adenokarzinome des Ösophagus nach Leitlinie

Literatur
1 Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology 2015; 149: 302
2 Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013; 14: 5598-5606
3 Porschen R, Buck A, Fischbach W et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0 – September 2015, AWMF-Registernummer: 021/023OL). Z Gastroenterol 2015; 53: 1291-1350
4 Wittekind C, Meyer HJ. TNM Klassifikation maligner Tumoren. 7. Aufl. Weinheim: Wiley-Blackwell; 2010
5 Pech O, May A, Manner H et al. Long Term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146: 652-660
6 Ngamruengphong S, Wolfsen HC, Wallace MB. Survival of patients with superficial esophageal adenocarcinoma after endoscopic treatment vs. surgery. Clin Gastroenterol Hepatol 2013; 11: 1424-1425
7 Manner H, Pech O, Heldmann Y et al. Efficacy, safety, and long term result of endoscopic treatment for early stage adenocarcinoma of the esophagus with low risk sm1 invasion. Clin Gastroenterol Hepatol 2013; 11: 630-635
8 Möhler M, Al-Batran SE, Andus T et al. S3-Leitlinie Magenkarzinom. Diagnostik und Therapie der Adenokarzinome des Magens und des gastroösophagealen Übergangs. Z Gastroenterol 2011; 49: 461-531
9 MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2011; 345: 725-730
10 Zheng B, Zheng W, Zhu Y et al. Role of chemoradiotherapy in treatment of resectable esophageal carcinoma: a meata-analysis. Chin Med J 2013; 126: 1178-1182
11 Ando N, Kato H, Igaki H et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012; 19: 68-74
12 Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology 2011; 12: 681-692
13 van Hagen P, Hulshof MCCM, van Lanschot JJB et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
14 Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
15 Ronellenfitsch U, Schwarzbach M, Hofheinz R et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (Review). Cochrane Database Syst Rev 2013; 5: CD008107
16 Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317
17 Bedenne L, Michel P, Bouché O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168
18 Allum WH, Blazeby JM, Griffin SM et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011; 60: 1449-1472
19 Ariga H, Nemoto K, Miyazaki S et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiation Oncology Biol Phys 2009; 75: 348-356
20 Crosby T, Hurt CN, Falk S et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentric, phase 2/3 randomised trial. Lancet Oncol 2013; 14: 627-637